CROSSJECT Accomplishes Key Milestones in ZEPIZURE® Manufacturing
CROSSJECT, a pioneering name in specialty pharmaceuticals, has made strides in its journey with ZEPIZURE®, an innovative treatment designed for emergency management of epileptic crises. Recently, the company reported a successful attainment of stability benchmarks for its Registration Batch of ZEPIZURE®, produced in collaboration with EUROFINS.
Positive Stability Data
The stability results reveal that the Registration Batch has satisfactorily met the six-month room temperature stability criteria. This achievement is a significant indicator of the product's reliability in various conditions, supporting its future market applications. CROSSJECT previously announced similar results from a previous batch, produced in December of the previous year, which showed encouraging nine-month stability results.
Regulatory Application Progress
As CROSSJECT advances toward securing Emergency Use Authorization, the manufacturing process is vital for the comprehensive regulatory filing required by the U.S. Food and Drug Administration (FDA). The gathered data will be included in the New Drug Application (NDA) for ZEPIZURE® aimed at establishing its availability in the U.S. market.
Collaboration with EUROFINS
EUROFINS, a respected Contract Development and Manufacturing Organization (CDMO), is presently focused on creating additional validation batches as part of the regulatory submission process. This ongoing collaboration not only paves the way for regulatory approvals but also strengthens the long-term relationship between CROSSJECT and EUROFINS.
Impact and Future Directions
CEO of CROSSJECT, Patrick Alexandre, expressed satisfaction with these positive results, indicating that they complement pending validation batch data crucial for completing the electronic dossier for ZEPIZURE®. He emphasized that this progress signifies confidence in their manufacturing capabilities and the adaptability of the ZENEO® platform.
If granted approval, ZEPIZURE® will enhance national preparedness against chemical threats while ensuring the availability of needle-free auto-injectors to patients and caregivers who may need them in critical situations.
About CROSSJECT and Its Innovations
CROSSJECT (Euronext: ALCJ) specializes in creating emergency solutions through its award-winning ZENEO® auto-injector platform. The company is not only focused on ZEPIZURE® but is also developing a range of products targeting allergic shocks, adrenal insufficiencies, and other urgent health conditions. With a significant $60 million partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA), the company is in a strong position to make substantial contributions to emergency medicine.
Frequently Asked Questions
What is ZEPIZURE® developed by CROSSJECT?
ZEPIZURE® is an innovative treatment designed to manage epileptic crises utilizing the advanced needle-free auto-injector technology of ZENEO®.
What recent milestones has CROSSJECT achieved?
CROSSJECT successfully completed a six-month stability evaluation for its Registration Batch of ZEPIZURE®, demonstrating its reliability for emergency use.
Why is the collaboration with EUROFINS significant?
EUROFINS plays a crucial role as a CDMO in producing validation batches, which are important for CROSSJECT's regulatory submissions and overall manufacturing strategy.
What are the key components of the regulatory submission?
The regulatory submission includes stability data, manufacturing batch details, and the NDA required for ZEPIZURE® to gain market approval from the FDA.
How does ZEPIZURE® contribute to U.S. national security?
If approved, ZEPIZURE® will enhance national preparedness against chemical threats, providing critical emergency solutions through its accessible delivery method.
